CA2524567A1

CA2524567A1 - Compositions and methods for the diagnosis and treatment of tumors of glial origin

Compositions and methods for the diagnosis and treatment of tumors of glial origin Download PDF

Info

Publication number: CA2524567A1
Authority: CA; Canada
Prior art keywords: antibody; seq; polypeptide; tat; amino acid
Prior art date: 2003-05-23
Legal status : Abandoned

Application number

CA002524567A

Other languages

English (en)

French (fr)

Inventor

Heidi Phillips

Current Assignee

Genentech Inc

Original Assignee

Individual

Priority date

2003-05-23

Filing date

2004-05-21

Publication date

2004-12-29

2004-05-21 Application filed by Individual filed Critical Individual

2004-12-29 Publication of CA2524567A1 publication Critical patent/CA2524567A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 308
206010028980 Neoplasm Diseases 0.000 title claims abstract description 184
238000011282 treatment Methods 0.000 title claims abstract description 54
239000000203 mixture Substances 0.000 title claims abstract description 31
230000002518 glial effect Effects 0.000 title claims description 22
238000003745 diagnosis Methods 0.000 title abstract description 9
241000124008 Mammalia Species 0.000 claims abstract description 50
210000004027 cell Anatomy 0.000 claims description 298
230000027455 binding Effects 0.000 claims description 172
102000015636 Oligopeptides Human genes 0.000 claims description 160
108010038807 Oligopeptides Proteins 0.000 claims description 160
239000000427 antigen Substances 0.000 claims description 100
108091007433 antigens Proteins 0.000 claims description 99
102000036639 antigens Human genes 0.000 claims description 99
108090000623 proteins and genes Proteins 0.000 claims description 89
102000004169 proteins and genes Human genes 0.000 claims description 77
239000003053 toxin Substances 0.000 claims description 62
231100000765 toxin Toxicity 0.000 claims description 62
108700012359 toxins Proteins 0.000 claims description 62
229940127089 cytotoxic agent Drugs 0.000 claims description 60
230000012010 growth Effects 0.000 claims description 55
231100000599 cytotoxic agent Toxicity 0.000 claims description 52
239000002254 cytotoxic agent Substances 0.000 claims description 51
239000011230 binding agent Substances 0.000 claims description 45
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 42
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 42
230000002401 inhibitory effect Effects 0.000 claims description 42
206010018338 Glioma Diseases 0.000 claims description 40
208000032612 Glial tumor Diseases 0.000 claims description 39
239000003795 chemical substances by application Substances 0.000 claims description 33
230000014509 gene expression Effects 0.000 claims description 32
238000012360 testing method Methods 0.000 claims description 30
102000004190 Enzymes Human genes 0.000 claims description 27
108090000790 Enzymes Proteins 0.000 claims description 27
230000002285 radioactive effect Effects 0.000 claims description 24
239000003242 anti bacterial agent Substances 0.000 claims description 21
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 21
230000001293 nucleolytic effect Effects 0.000 claims description 21
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 20
229930195731 calicheamicin Natural products 0.000 claims description 20
238000001514 detection method Methods 0.000 claims description 18
230000034994 death Effects 0.000 claims description 17
230000001965 increasing effect Effects 0.000 claims description 16
229940088710 antibiotic agent Drugs 0.000 claims description 14
241000894006 Bacteria Species 0.000 claims description 13
239000002246 antineoplastic agent Substances 0.000 claims description 13
210000004498 neuroglial cell Anatomy 0.000 claims description 8
230000005855 radiation Effects 0.000 claims description 8
210000004556 brain Anatomy 0.000 claims description 5
108020004999 messenger RNA Proteins 0.000 claims description 5
108090000765 processed proteins & peptides Proteins 0.000 description 436
102000004196 processed proteins & peptides Human genes 0.000 description 435
229920001184 polypeptide Polymers 0.000 description 431
101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 description 296
101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 296
101710175714 Tyrosine aminotransferase Proteins 0.000 description 296
125000003275 alpha amino acid group Chemical group 0.000 description 241
239000002773 nucleotide Substances 0.000 description 193
125000003729 nucleotide group Chemical group 0.000 description 193
108091026890 Coding region Proteins 0.000 description 135
108010076504 Protein Sorting Signals Proteins 0.000 description 106
239000002299 complementary DNA Substances 0.000 description 98
150000007523 nucleic acids Chemical class 0.000 description 97
201000011510 cancer Diseases 0.000 description 96
235000018102 proteins Nutrition 0.000 description 74
102000039446 nucleic acids Human genes 0.000 description 55
108020004707 nucleic acids Proteins 0.000 description 55
108020004414 DNA Proteins 0.000 description 54
239000012634 fragment Substances 0.000 description 53
108091028043 Nucleic acid sequence Proteins 0.000 description 43
239000000523 sample Substances 0.000 description 40
239000003814 drug Substances 0.000 description 38
108060003951 Immunoglobulin Proteins 0.000 description 35
102000018358 immunoglobulin Human genes 0.000 description 35
210000001519 tissue Anatomy 0.000 description 33
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
238000002360 preparation method Methods 0.000 description 31
230000001225 therapeutic effect Effects 0.000 description 28
208000035475 disorder Diseases 0.000 description 27
229940088598 enzyme Drugs 0.000 description 25
239000011800 void material Substances 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 23
238000004519 manufacturing process Methods 0.000 description 21
229940024606 amino acid Drugs 0.000 description 20
125000000539 amino acid group Chemical group 0.000 description 20
230000002062 proliferating effect Effects 0.000 description 20
230000003068 static effect Effects 0.000 description 20
150000001413 amino acids Chemical class 0.000 description 19
210000004881 tumor cell Anatomy 0.000 description 18
108010087819 Fc receptors Proteins 0.000 description 16
102000009109 Fc receptors Human genes 0.000 description 16
230000000295 complement effect Effects 0.000 description 16
239000005557 antagonist Substances 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
239000012636 effector Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
210000004408 hybridoma Anatomy 0.000 description 13
238000004113 cell culture Methods 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
239000013598 vector Substances 0.000 description 12
102000053602 DNA Human genes 0.000 description 11
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
239000013604 expression vector Substances 0.000 description 11
230000002265 prevention Effects 0.000 description 11
230000008569 process Effects 0.000 description 11
241000894007 species Species 0.000 description 11
238000003556 assay Methods 0.000 description 10
230000006870 function Effects 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
230000003389 potentiating effect Effects 0.000 description 10
206010035226 Plasma cell myeloma Diseases 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
230000004927 fusion Effects 0.000 description 9
239000012528 membrane Substances 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
241000588724 Escherichia coli Species 0.000 description 8
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
231100000433 cytotoxic Toxicity 0.000 description 8
230000001472 cytotoxic effect Effects 0.000 description 8
201000000050 myeloid neoplasm Diseases 0.000 description 8
239000000556 agonist Substances 0.000 description 7
230000003115 biocidal effect Effects 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
238000004590 computer program Methods 0.000 description 7
238000012258 culturing Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
206010027476 Metastases Diseases 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
230000030833 cell death Effects 0.000 description 6
230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
229940072221 immunoglobulins Drugs 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
102000040430 polynucleotide Human genes 0.000 description 6
108091033319 polynucleotide Proteins 0.000 description 6
239000002157 polynucleotide Substances 0.000 description 6
230000009467 reduction Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
230000009870 specific binding Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 5
241000283984 Rodentia Species 0.000 description 5
-1 agarose) Chemical class 0.000 description 5
239000000074 antisense oligonucleotide Substances 0.000 description 5
238000012230 antisense oligonucleotides Methods 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
230000001086 cytosolic effect Effects 0.000 description 5
230000009036 growth inhibition Effects 0.000 description 5
230000009401 metastasis Effects 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
238000000746 purification Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000001509 sodium citrate Substances 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
210000005253 yeast cell Anatomy 0.000 description 5
206010003571 Astrocytoma Diseases 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 4
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000013068 control sample Substances 0.000 description 4
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
230000006378 damage Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000013467 fragmentation Methods 0.000 description 4
238000006062 fragmentation reaction Methods 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
125000005647 linker group Chemical group 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000009826 neoplastic cell growth Effects 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000005406 washing Methods 0.000 description 4
102000000412 Annexin Human genes 0.000 description 3
108050008874 Annexin Proteins 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
201000010133 Oligodendroglioma Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
230000018199 S phase Effects 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000000356 contaminant Substances 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
239000000539 dimer Substances 0.000 description 3
229960003668 docetaxel Drugs 0.000 description 3
229960004679 doxorubicin Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000008676 import Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
101150032953 ins1 gene Proteins 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
238000011275 oncology therapy Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000002823 phage display Methods 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
238000003156 radioimmunoprecipitation Methods 0.000 description 3
238000012552 review Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 2
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
102100029571 Immunoglobulin J chain Human genes 0.000 description 2
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
102100020880 Kit ligand Human genes 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
230000027311 M phase Effects 0.000 description 2
108091022875 Microtubule Proteins 0.000 description 2
102000029749 Microtubule Human genes 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
101710149951 Protein Tat Proteins 0.000 description 2
238000011529 RT qPCR Methods 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
108010039445 Stem Cell Factor Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
229940123237 Taxane Drugs 0.000 description 2
241001116498 Taxus baccata Species 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000011923 Thyrotropin Human genes 0.000 description 2
108010061174 Thyrotropin Proteins 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
229940122803 Vinca alkaloid Drugs 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000011230 antibody-based therapy Methods 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000012412 chemical coupling Methods 0.000 description 2
229940047120 colony stimulating factors Drugs 0.000 description 2
230000024203 complement activation Effects 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
239000000032 diagnostic agent Substances 0.000 description 2
229940039227 diagnostic agent Drugs 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 2
150000004662 dithiols Chemical class 0.000 description 2
230000000235 effect on cancer Effects 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
238000002509 fluorescent in situ hybridization Methods 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
230000036541 health Effects 0.000 description 2
108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
229940022353 herceptin Drugs 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
239000012642 immune effector Substances 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
210000004688 microtubule Anatomy 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000017066 negative regulation of growth Effects 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
208000023958 prostate neoplasm Diseases 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000005180 public health Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000009987 spinning Methods 0.000 description 2
208000017572 squamous cell neoplasm Diseases 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
241000212977 Andira Species 0.000 description 1
108090000672 Annexin A5 Proteins 0.000 description 1
102000004121 Annexin A5 Human genes 0.000 description 1
108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
206010065869 Astrocytoma, low grade Diseases 0.000 description 1
101710192393 Attachment protein G3P Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710169873 Capsid protein G8P Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
239000012624 DNA alkylating agent Substances 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
208000021994 Diffuse astrocytoma Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000724791 Filamentous phage Species 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000005409 Gliomatosis cerebri Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
101710156564 Major tail protein Gp23 Proteins 0.000 description 1
206010026659 Malignant oligodendroglioma Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
108010003044 Placental Lactogen Proteins 0.000 description 1
239000000381 Placental Lactogen Substances 0.000 description 1
201000007288 Pleomorphic xanthoastrocytoma Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
108090000103 Relaxin Proteins 0.000 description 1
102000003743 Relaxin Human genes 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
108010084592 Saporins Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
101150117115 V gene Proteins 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000863480 Vinca Species 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
239000000488 activin Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
201000007538 anal carcinoma Diseases 0.000 description 1
206010002224 anaplastic astrocytoma Diseases 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003817 anthracycline antibiotic agent Substances 0.000 description 1
239000000868 anti-mullerian hormone Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000003443 bladder cell Anatomy 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000002032 cellular defenses Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
230000010428 chromatin condensation Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000005574 cross-species transmission Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
HVCNNTAUBZIYCG-UHFFFAOYSA-N ethyl 2-[4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenoxy]propanoate Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=NC2=CC=C(Cl)C=C2S1 HVCNNTAUBZIYCG-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
201000001169 fibrillary astrocytoma Diseases 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000003500 gene array Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000002409 gliosarcoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000013388 immunohistochemistry analysis Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229960003151 mercaptamine Drugs 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
201000004058 mixed glioma Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000027498 negative regulation of mitosis Effects 0.000 description 1
208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
206010073131 oligoastrocytoma Diseases 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940055729 papain Drugs 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
208000030940 penile carcinoma Diseases 0.000 description 1
201000008174 penis carcinoma Diseases 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
201000002628 peritoneum cancer Diseases 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108010087851 prorelaxin Proteins 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
201000003804 salivary gland carcinoma Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000010323 transrectal needle biopsy Methods 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000012991 uterine carcinoma Diseases 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
238000001262 western blot Methods 0.000 description 1